Plus Therapeutics Releases Early-Cut Data From Cancer Studies For Brain Cancer Settings
Portfolio Pulse from Vandana Singh
Plus Therapeutics Inc (NASDAQ:PSTV) has released interim updates from its ReSPECT-GBM and ReSPECT-LM studies of rhenium (186Re) obisbemeda for recurrent glioblastoma and leptomeningeal metastases. The data, presented at the Society of Nuclear Medicine & Molecular Imaging Annual Meeting, showed that a single dose of rhenium (186Re) obisbemeda was generally safe and well-tolerated, with no dose-limiting toxicities and minimal systemic radiation exposure. The company's shares are up 1.59% at $2.56.
June 29, 2023 | 4:39 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Plus Therapeutics' shares are up following the release of positive interim data from its cancer studies.
The release of positive interim data from its cancer studies has led to an increase in Plus Therapeutics' share price. This is likely due to increased investor confidence in the company's product.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100